Iktos is an innovative company specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically medicinal chemistry and new drug design. The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D
The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital - all joining as new investors
Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics - an AI-driven automated end-to-end drug discovery service